Please assess the completion status of the following clinical trial:

Trial Title: Spectroscopic Imaging at 4T: A Drug Challenge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be male volunteers between the ages of 21-45~* Non-smoking participants are preferred, but will admit those who smoke less than 5 cigarettes per day~* Participants must be able to read screening materials including consent form and give informed consent~Exclusion Criteria:~* Participants cannot meet DSM-IV criteria for lifetime and/or current mood, anxiety, psychotic, and alcohol/drug use disorders as identified by the SCID~* Participants cannot be taking any prescription medication (except oral contraceptives, certain short-term anti-fungal agents, and some topical creams for dermal conditions) or nutritional supplements~* Participants cannot be taking any psychotropic medications~* Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders.~* Participants cannot have any conditions that are contraindicated for MRI~* Participants cannot have a family history of alcoholism~* Participants cannot have any abnormal blood chemistries/urinalysis results or any other medical condition that may affect drug disposition (e.g., Hepatitis C)~* Participants cannot have current or past cardiac problems, and they also cannot have a family history of sudden death or ventricular arrhythmia~* Participants who, in the investigators' judgment, will not likely be able to comply with the study protocol.~* Participants cannot have any clinically significant findings in the structural anatomic brain scans (per the MRI report read by a board-certified radiologist).

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Alprazolam (A) (Type: ACTIVE_COMPARATOR): Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
- Dextroamphetamine (D) (Type: ACTIVE_COMPARATOR): Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
- Placebo (P) (Type: PLACEBO_COMPARATOR): Placebo gel-capsule, single-dose, 1-day

Based on this trial design, predict the completion outcome and termination type (if applicable).